Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
NCT04888481Phase 2Recruiting
- Sponsor
- University of Alberta
- Start
- Feb 2022
- Primary completion
- Aug 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-HA-DOTATATE in neuroendocrine tumors (NETs), sponsored by University of Alberta. Started Feb 2022; status: recruiting.
02
Drugs
68Ga-HA-DOTATATE
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04888481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888481.